Foundayo would be the second GLP-1 pill cleared in the EU after Novo's Wegovy pill. The European Commission now makes the final call on launch.
Recap by typeshit. Full story at CNBC.
The clinic says the choice should weigh long term outcomes and overall health, not just pounds lost, and that no single treatment fits everyone.
15:25
Doctor Alex says Ozempic works but comes with a catch, and walks through what he thinks people misunderstand about GLP-1 drugs.
Lilly reports on Oct. 29, and Zacks expects investors to focus on Foundayo after the oral GLP-1 brought in $98 million in its first full quarter on sale.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
At the Cambridge diabetes seminar in Kochi, Mithal faced Prof Bill Herman of the University of Michigan, with the audience joining in.
A plain-language look at the science behind Lilly's oral GLP-1 pill, aimed at people finding weight harder to manage in middle age.
Loading…